Eric Easom - 15 Mar 2024 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Executive Officer, Director
Signature
/s/ Lucy Day, Attorney-in-Fact for Eric Easom
Issuer symbol
ANTX
Transactions as of
15 Mar 2024
Net transactions value
$0
Form type
4
Filing time
18 Mar 2024, 19:26:24 UTC
Previous filing
04 Jan 2024
Next filing
18 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANTX Common Stock Award $0 +99,000 +4648% $0.000000 101,130 15 Mar 2024 Direct F1
holding ANTX Common Stock 1,015,766 15 Mar 2024 See Footnote F2
holding ANTX Common Stock 97,058 15 Mar 2024 See Footnote F3
holding ANTX Common Stock 97,058 15 Mar 2024 See Footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (right to buy) Award $0 +198,000 $0.000000 198,000 15 Mar 2024 Common Stock 198,000 $3.00 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These restricted stock units vest as follows: 1/16th of the shares vests quarterly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.
F2 Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.
F3 Consists of shares of Common Stock held by the C Easom Irrevocable Trust dated October 8, 2021.
F4 Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.
F5 The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2024, subject to the Reporting Person's continuous service as of such date.